Cell Therapy News & Insights | RoslinCT

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing, Partnerships, Tech Transfer

January 07, 2026

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-only) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing, Partnerships, Tech Transfer

December 16, 2025

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-only) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing, Tech Transfer

March 11, 2025

RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

A Checklist for a Successful Cell Therapy Tech Transfer

eBook, MS&T, Tech Transfer

November 01, 2022

A Checklist for a Successful Cell Therapy Tech Transfer

[EBOOK] Key Considerations for a Successful Cell Therapy Tech Transfer

Cell Therapy, eBook, Tech Transfer

November 01, 2022

[EBOOK] Key Considerations for a Successful Cell Therapy Tech Transfer